GEHC vs RPRX

GEHC presents a stark contrast between analyst optimism and deterministic fundamental health. The Piotroski F-Score of 3/9 indicates weak financial health, and the current price of $72.91 trades at a significant premium to both the Graham Number ($48.02) and the Intrinsic Value ($31.50). While the company maintains strong ROE (22.38%) and consistent earnings beats, the negative YoY earnings growth (-17.70%) and bearish technical trend suggest a period of instability. The stock is fundamentally overvalued based on deterministic models, though it remains cheaper than the broader healthcare sector average P/E.

RPRX exhibits a stable but mediocre Piotroski F-Score of 4/9, indicating average financial health without strong momentum. The stock is significantly overvalued, trading at $50.00 despite a Graham Number of $24.60 and an Intrinsic Value of $36.49. Aggressive insider selling by the CFO and a sharp decline in recent Q/Q EPS growth (-67.5%) signal significant internal caution. While analyst sentiment remains a 'buy', the deterministic data and valuation gap suggest a high risk of a price correction.